UTAH MEDICAL PRODUCTS INC Initial Statement of Beneficial Ownership
Utah Medical Products Inc. director Kevin Timken reported an initial beneficial ownership position that includes a stock option to buy 10,000 shares of the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Utah Medical Products Inc. director Kevin Timken reported an initial beneficial ownership position that includes a stock option to buy 10,000 shares of the company’s common stock. The option has an exercise price of $58.10 per share, becomes exercisable on 10/01/2026, and expires on 10/31/2035.
The option vests 25% on 10/01/2026, with an additional 6.25% vesting on 01/01/2027 and on the first day of each calendar quarter thereafter, becoming fully exercisable on 10/01/2029. This filing reflects his status as a director and provides transparency into his equity-based compensation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option - Right to Buy | -- | -- | -- |
Footnotes (1)
- F1. Option vests 25% on 10/01/2026 and 6.25% on 01/01/2027 and the first day of each calendar quarter thereafter. Fully exercisable on 10/01/2029.
AI-generated analysis. How Rhea-AI works. Not financial advice.